Home > News > Nanogen Receives 510(k) Clearance
March 29th, 2006
Nanogen Receives 510(k) Clearance
Abstract:
Nanogen, Inc. (Nasdaq: NGEN), developer of advanced diagnostic products, announced today that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market its StatusFirst(TM) CHF NT-proBNP EDTA plasma test to aid in the diagnosis of individuals suspected of having congestive heart failure (CHF).
Source:
prnewswire
Bookmark:
| Related News Press |
Nanomedicine
Exosomes: A potential biomarker and therapeutic target in diabetic cardiomyopathy November 8th, 2024
Unveiling the power of hot carriers in plasmonic nanostructures August 16th, 2024
Announcements
Nanotechnology: Flexible biosensors with modular design November 8th, 2024
Exosomes: A potential biomarker and therapeutic target in diabetic cardiomyopathy November 8th, 2024
Turning up the signal November 8th, 2024
Nanofibrous metal oxide semiconductor for sensory face November 8th, 2024
 |
||
 |
||
| The latest news from around the world, FREE | ||
 |
||
|
|
||
| Premium Products | ||
 |
||
|
Only the news you want to read!
Learn More |
||
 |
||
|
Full-service, expert consulting
Learn More |
||
|
|
||